The American pharmaceutical Pfizer stops the development of an obesity pill that investors eagerly await. According to Bloomberg financial press agency, this is a hefty setback for Pfizer when it comes to competing with the popular weight -loss pricks of industryers Novo Nordisk and Eli Lilly.
ttn-3
